{
    "clinical_study": {
        "@rank": "60539", 
        "arm_group": {
            "arm_group_label": "Hemospray to treat lower GI bleeds"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the performance of Hemospray for the teatment of nonvariceal lower\n      gastrointestinal bleeding."
        }, 
        "brief_title": "Study of Hemospray for Lower Gastrointestinal Hemorrhage", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colonic Diverticula", 
            "Angiodysplasia", 
            "Colonic Polyp"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colonic Polyps", 
                "Diverticulum, Colon", 
                "Diverticulum", 
                "Gastrointestinal Hemorrhage", 
                "Hemorrhage", 
                "Angiodysplasia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient in which Hemospray is used to treat an endoscopically confirmed\n             nonvariceal lower GI bleed requiring hemostasis\n\n        Exclusion Criteria:\n\n          -  Less than 19 years old\n\n          -  Unwilling or unable to sign and date the informed consent\n\n          -  Pregnant, lactating or planning to become pregnant within 30 days of the procedure\n\n          -  Contraindicated to undergo colonoscopy\n\n        Medical/Endoscopic Exclusion Criteria\n\n          -  Actual or suspected lower GI perforation or fistula\n\n          -  Bleeding originating from inflammatory bowel disease (e.g., Crohn's disease or\n             ulcerative colitis)\n\n          -  Actual or suspected ischemic colitis or infectious colitis\n\n          -  Unable to visualize site of active bleeding (such as suspected diverticular bleed\n             where source is unable to be identified)\n\n          -  Unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the\n             colonoscope)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "clinical sites"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099435", 
            "org_study_id": "12-007"
        }, 
        "intervention": {
            "arm_group_label": "Hemospray to treat lower GI bleeds", 
            "description": "The Hemospray\u2122 device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray\u2122 material. Hemospray\u2122 is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.", 
            "intervention_name": "Hemospray", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastriointestinal", 
            "Lower gastriointestinal", 
            "Digestive", 
            "Hemostasis", 
            "Recurrent bleeding", 
            "Hemospray"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "last_name": "Daphne Meyer", 
                "phone": "780-429-3050"
            }, 
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta"
                }, 
                "name": "University of Alberta"
            }, 
            "investigator": {
                "last_name": "Chris Teshima, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)", 
        "overall_contact": {
            "email": "tconley@medinst.com", 
            "last_name": "Travis B Conley, PhD", 
            "phone": "765-463-7537"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of device related adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099435"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of recurrent bleeding that occurs outside the blood vessel", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "source": "Cook", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cook", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}